The new work was supported by a grant from AbbVie to the Medical University of Vienna. Dr. Smolen, who did not respond to a request for comments, and his colleagues disclosed financial ties to AbbVie and multiple other drug companies.
Related Articles
European Beacon for Rheumatology
Josef S. Smolen, MD, led the way for outcomes measures and a scientifically based training program
Antiphospholipid Antibody Testing Update
Successes, challenges, and controversies of diagnostic methods for APS
More Data for Treat to Target: Post-Hoc Analysis of Large RA Clinical Trials Supports Treat-to-Target Recommendations
A post-hoc analysis of data from two large clinical trials supports treat-to-target recommendations for patients with rheumatoid arthritis. The research found baseline disease activity was the strongest predictor of a patient’s insufficient response to initial therapy at six months…
Target Remission
Strategies to identify and track remission in your RA patients